IPP Bureau
FDA reviews AstraZeneca’s Saphnelo for subcutaneous use in Lupus
By IPP Bureau - February 05, 2026
A final decision on the updated application is expected in the first half of 2026, while intravenous (IV) Saphnelo remains commercially available
GPT Healthcare reports 12% revenue growth in 9M FY26, strengthens clinical capabilities
By IPP Bureau - February 04, 2026
The company maintained a competitive ARPOB while steadily improving occupancy, driven by higher patient volumes and efficient capacity utilization
Sanofi’s Venglustat shows breakthrough results in rare neurological Gaucher disease
By IPP Bureau - February 04, 2026
Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs
FDA launches PreCheck program to bring drug manufacturing back to US
By IPP Bureau - February 04, 2026
The program seeks to boost regulatory predictability, support construction of US-based manufacturing sites
Richter’s FYLREVY to transform menopause care in Europe?
By IPP Bureau - February 04, 2026
The recommendation covers FYLREVY 14.2 mg and 18.9 mg for non-hysterectomised postmenopausal women experiencing oestrogen deficiency symptoms at least 12 months after their last menses
ALX Oncology’s evorpacept shows promise in HER2-positive breast cancer
By IPP Bureau - February 04, 2026
The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy
Siemens Healthineers launches €10 million R&D hub in Swords, Ireland
By IPP Bureau - February 04, 2026
The facility is dedicated to breakthrough innovations in laboratory instruments that detect infectious diseases, cancer, and blood disorders
_Limited.jpg "Arctic Vision expands global reach with acquisition of MDCO Technology’s ophthalmic device business")
Onchilles Pharma gets FDA green light for first-in-human trials of breakthrough cancer therapy
By IPP Bureau - February 04, 2026
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
Pfizer’s monthly obesity drug shows breakthrough weight loss in Phase 2b trial
By IPP Bureau - February 04, 2026
The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated
Cirena launches to revolutionize long RNA production for CRISPR & gene editing
By IPP Bureau - February 04, 2026
As CRISPR and prime editing applications advance, researchers increasingly rely on longer guide RNAs to boost editing efficiency and reduce off-target effects
Epigenica launches EpiFinder Analysis Service to accelerate Epigenomic research
By IPP Bureau - February 04, 2026
The new service delivers end-to-end support, managing every stage of an epigenomics project
China nod to Darolutamide for metastatic hormone-sensitive prostate cancer
By IPP Bureau - February 04, 2026
The approval follows the pivotal Phase III ARANOTE trial, which demonstrated that darolutamide plus ADT cut the risk of radiological progression or death by 46% compared to placebo plus ADT
India’s silent oral cancer crisis: Early detection could save thousands
By IPP Bureau - February 04, 2026
SPARC announces receipt of priority review voucher associated with Sezaby approval
By IPP Bureau - February 04, 2026
A PRV is a tradable voucher granted by the FDA to encourage the development of new treatments for rare pediatric diseases
